ConductScience.org, home

Paper41599403

Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.

Fermo AD and 4 others. Molecules, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents. Papers, record 41599403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41599403

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.
PubMed
Journal
Molecules
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-07-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PyrazolesMajor topic
Antineoplastic AgentsMajor topic
Biological ProductsMajor topic
TriazolesMajor topic
Humans
Molecular Structure
Animals

Source PubMed

Download CSV of topics

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139193301
Design, synthesis and potent anti-pancreatic cancer activity of new pyrazole derivatives bearing chalcone, thiazole and thiadiazole moieties: gene expression, DNA fragmentation, cell cycle arrest and SAR.
RSC Adv2024https://conductscience.org/library/papers/39193301PubMed
225339989Activity artifacts in drug discovery and different facets of compound promiscuity.F1000Res2014https://conductscience.org/library/papers/25339989PubMed
312556221Indisulam: an anticancer sulfonamide in clinical development.Expert Opin Investig Drugs2003https://conductscience.org/library/papers/12556221PubMed
438117940Identification of novel sulfathiazole-triazolo-chalcone hybrids as VEGFR-2/EGFR dual inhibitors with antiangiogenic activity and apoptotic induction.Arch Pharm (Weinheim)2024https://conductscience.org/library/papers/38117940PubMed
534939695Anticancer activity of novel 3-(furan-2-yl)pyrazolyl and 3-(thiophen-2-yl)pyrazolyl hybrid chalcones: Synthesis and in vitro studies.Arch Pharm (Weinheim)2022https://conductscience.org/library/papers/34939695PubMed
628488435Chalcone: A Privileged Structure in Medicinal Chemistry.Chem Rev2017https://conductscience.org/library/papers/28488435PubMed
7319864061,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.Eur J Med Chem2020https://conductscience.org/library/papers/31986406PubMed
837331408Design, synthesis, in vitro and in silico evaluation of anti-colorectal cancer activity of curcumin analogues containing 1,3-diphenyl-1H-pyrazole targeting EGFR tyrosine kinase.Biochim Biophys Acta Gen Subj2023https://conductscience.org/library/papers/37331408PubMed
936651540Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway.Acta Pharm2022https://conductscience.org/library/papers/36651540PubMed
1039817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
1135964843Synthesis and biological testing of 3,5-bis(arylidene)-4-piperidone conjugates with 2,5-dihydro-5H-1,2-oxaphospholenes.Bioorg Med Chem Lett2022https://conductscience.org/library/papers/35964843PubMed
1211433435Click Chemistry: Diverse Chemical Function from a Few Good Reactions.Angew Chem Int Ed Engl2001https://conductscience.org/library/papers/11433435PubMed
1339496648Design, in silico studies and biological evaluation of novel chalcones tethered triazolo[3,4-a]isoquinoline as EGFR inhibitors targeting resistance in non-small cell lung cancer.Sci Rep2024https://conductscience.org/library/papers/39496648PubMed
1427697050Hybrid Compounds as Multitarget Directed Anticancer Agents.Curr Top Med Chem2017https://conductscience.org/library/papers/27697050PubMed
1528685693Multi-Targeted Anticancer Agents.Curr Top Med Chem2017https://conductscience.org/library/papers/28685693PubMed
1638998962Synthesis, Anticancer Activity, and Molecular Docking of New 1,2,3-Triazole Linked Tetrahydrocurcumin Derivatives.Molecules2024https://conductscience.org/library/papers/38998962PubMed
1734572538Tailored Functionalization of Natural Phenols to Improve Biological Activity.Biomolecules2021https://conductscience.org/library/papers/34572538PubMed
1835358822Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates.Bioorg Chem2022https://conductscience.org/library/papers/35358822PubMed
1916220969Designed multiple ligands. An emerging drug discovery paradigm.J Med Chem2005https://conductscience.org/library/papers/16220969PubMed
2030343043Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.Pharmacol Rep2019https://conductscience.org/library/papers/30343043PubMed

See all 80 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41599403

GET https://conductscience.org/api/papers/v1/41599403/references?page=2